Close

Bausch + Lomb Announces Statistically Significant Topline Results From The First Phase 3 Trial Of NOV03 (perfluorohexyloctane) In Dry Eye Disease Associated With Meibomian Gland Dysfunction

Go back to Bausch + Lomb Announces Statistically Significant Topline Results From The First Phase 3 Trial Of NOV03 (perfluorohexyloctane) In Dry Eye Disease Associated With Meibomian Gland Dysfunction
CBC Holding Company (NYSE: BHC) Delayed: 10.61 +0.12 (1.14%)
Previous Close $10.49    52 Week High $4.75 
Open $10.46    52 Week Low $4.75 
Day High $10.80    P/E N/A 
Day Low $10.45    EPS $0.00 
Volume 3,815,212       

CBC Holding Company (NYSE: BHC) Delayed: 10.61 +0.12 (1.14%)
Previous Close $10.49    52 Week High $4.75 
Open $10.46    52 Week Low $4.75 
Day High $10.80    P/E N/A 
Day Low $10.45    EPS $0.00 
Volume 3,815,212       

VALEANT PHARMACEUTICALS INTERNATIONAL (NYSE: VRX) Delayed: 23.40 --0 (-0%)
Previous Close $23.40    52 Week High $119.86 
Open $23.40    52 Week Low $13.77 
Day High $23.40    P/E N/A 
Day Low $23.40    EPS $0.00 
Volume 378,733